Navigation Links
VENENUM Biodesign to Exhibit at SBS
Date:3/22/2011

HAMILTON, N.J., March 22, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today that it will be exhibiting at the 17th SBS Annual Conference & Exhibition at the Gaylord Palms Resort and Convention Center in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will be exhibiting at booth #524.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign Compound Collection, which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department, which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "VENENUM is well-positioned with full ranging 'Gene to Lead' capabilities in early drug discovery to partner with pharma and non-profits. We are actively seeking those collaborations. VENENUM is also working to identify hits against novel targets and advance these through our Medicinal Chemistry."

To find out more, please visit http://www.venenumbiodesign.com.

Contact:

Maria Webb, Ph.D.
Chief Scientific Officer (CSO)
mwebb@venenumbiodesign.com
877.950.1032
http://www.venenumbiodesign.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VENENUM Biodesign
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
2. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
3. Nanowires exhibit giant piezoelectricity
4. At RSNA, DR Systems Will Exhibit New Unity v-Series Web PACS
5. WAVE Conference and Exhibition 2011 Taking Products to Market incorporating Micro & Nano Technology
6. Graphene exhibits bizarre new behavior well suited to electronic devices
7. Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York
8. PRA International Exhibits at European Hematology Association Congress
9. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
10. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
11. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):